|Report Code: PP10276||Published: January 2020||Available format:|
|Therapeutic Area(s):||Oncology | Metabolic | Infectious | Ophthalmology | Neurology | Others||Report Type: Mechanism of Action Reports|
Cyclin-dependent kinases (CDKs) can be identified as protein kinases that require a separate cyclin subunit, which provides domains for enzymatic activity. CDKs play a major role in modulating transcription and controlling cell division. Based on these functions, the CDK can be classified into three cell-cycle-related subfamilies, such as CDK1, CDK4, and CDK5, and five transcriptional subfamilies, such as CDK7, CDK8, CDK9, CDK11, and CDK20. In addition, dysregulation of these protein kinases is associated with cancer initiation and progression. Therefore, inhibition of CDKs has emerged as a novel approach in cancer therapy. The therapeutic potential of CDK inhibitors is also being evaluated in diseases, such as diabetes, renal disorders, neurodegenerative conditions, and infectious diseases. The CDK inhibitors can be further classified into CDK1, CDK2, CDK4, CDK5, and CDK6 inhibitors. The primary function of these inhibitors is to block the proliferation of cells by blocking the G1 phase of cell cycle.
Verzenio (Eli Lilly and Company), Kisqali (Novartis AG), and Ibrance (Pfizer Inc.) are some of the approved CDK inhibitors.
Positive clinical trial results and strategic advancements are expected to drive the CDK inhibitors pipeline. Moreover, the issuance of patents helps in achieving different milestones in the form of grants and designations from regulatory bodies and institutes, including the United States Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the National Institutes of Health (NIH).
As of December 2019, there were 10+ pipeline and marketed products.
Some of the key players developing CDK inhibitors for the treatment of various indications, include Eli Lilly and Company, Novartis AG, Pfizer Inc., MEI Pharma Inc., Cyclacel Pharmaceuticals Inc., Merck & Co., Tiziana Life Sciences, Onconova Therapeutics, Novartis International AG, and AstraZeneca plc.
Some highlights of the report “Cyclin-Dependent Kinase (CDK) Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” have been mentioned below: